Orion Oyj (OTCMKTS:ORINY) Hits New 1-Year High – What’s Next?

Orion Oyj (OTCMKTS:ORINY)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.57 and last traded at $30.57, with a volume of 306 shares. The stock had previously closed at $29.76.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a report on Tuesday, February 4th.

Orion Oyj Price Performance

The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $8.63 billion, a PE ratio of 24.26 and a beta of 0.25. The firm’s fifty day simple moving average is $26.95 and its 200-day simple moving average is $25.50.

Orion Oyj (OTCMKTS:ORINY) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The firm had revenue of $463.41 million during the quarter. On average, research analysts forecast that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Orion Oyj Increases Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th will be issued a dividend of $0.4478 per share. This is a boost from Orion Oyj’s previous dividend of $0.24. The ex-dividend date is Monday, April 7th. Orion Oyj’s payout ratio is presently 26.40%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.